# Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Source: https://onco.cc/trials/nct05710406/  
OnCo record `nct05710406` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of encorafenib and cetuximab in colorectal cancer, run by Alliance for Clinical Trials in Oncology, active but no longer recruiting.

## Summary

Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer is a phase 2/3, randomised interventional study registered as NCT05710406 by Alliance for Clinical Trials in Oncology, with a registry enrolment figure of 1 participants, started 2023-08-16 and due to reach its primary completion in 2034-06-01. Interventions recorded: Encorafenib; Cetuximab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Patient Observation. Conditions listed: Colon Adenocarcinoma; Microsatellite Stable Colon Carcinoma; Stage IIB Colon Cancer AJCC v8; Stage IIC Colon Cancer AJCC v8; Stage III Colon Cancer AJCC v8. Primary outcome: Circulating tumor deoxyribonucleic acid (ctDNA) clearance rate (Phase II; ctDNA positive cohort); tDNA recurrence-free survival rate (ctDNA-RFS) (Phase II; ctDNA negative cohort); Disease free survival (DFS) (Phase III). Colorectal eligibility wording from the registry: "* Pre-registration for central tumor testing will occur after colon resection". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT05710406
- Phase: 2/3
- Setting: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer
- Sponsor: Alliance for Clinical Trials in Oncology
- Enrolled: 1

## Sources

- ClinicalTrials.gov NCT05710406: https://clinicaltrials.gov/study/NCT05710406

## Connected records

- cancers: [BRAF V600E-mutant colorectal cancer](https://onco.cc/cancers/braf-v600e-colorectal/), [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Cetuximab](https://onco.cc/drugs/cetuximab/), [Encorafenib](https://onco.cc/drugs/encorafenib/)
- companies: [Alliance for Clinical Trials in Oncology](https://onco.cc/companies/alliance-oncology/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct05710406.json